BGI
BGI Americas, Advaite Form SARS-CoV-2 Testing Partnership
Through the deal, BGI Americas will offer its PCR-based SARS-CoV-2 detection kit with Advaite's COVID-19 immunoassay, both of which have FDA authorization.
BGI Genomics Nabs CE Mark for Colorectal Cancer Screening Test
The real-time PCR test can detect abnormal methylation of SDC2, ADHFE1, and PPP2R5C genes in stool DNA, which are markers for colorectal cancer cells.
BGI Bloodstream Pathogen Nucleic Acid Detection Kit Gets CE Mark
The kit, developed by BGI Patho-Genesis Pharmaceutical Technology, is designed to construct a metagenomic sequencing library directly from clinical samples.
In Brief This Week: Illumina, Thermo Fisher Scientific, FIND, and More
News items for the in vitro diagnostics industry for the week of Sept. 28, 2020.
BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests
Both RT-PCR tests are for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B from throat swab samples.